What to Know About Relapsed Disease Treatment After 12 Months in DLBCL
By The Fellow on Call - Last Updated: October 20, 2023In a previous episode, “The Fellow on Call” hosts Ronak Mistry, DO; Vivek Patel, MD; and Dan Hausrath, MD; focused their episode on primary refractory diffuse large B-cell lymphoma (DLBCL). Now, they’re back with part one of a two-part discussion surrounding relapsed DLBCL.
The episode talks about how to approach relapsed disease after 12 months, how to approach relapse with central nervous system (CNS) involvement, the role of chimeric antigen receptor (CAR)-T therapy versus autologous transplant in this setting, and how to approach treatment in patients who are poor candidates for autologous CAR-T.
This podcast originally appeared on thefellowoncall.com.
Advertisement
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.